Navigation Links
ChanTest Initiates Project for the US FDA to Improve Understanding of the Interaction of Tobacco Products with Human Nicotinic Receptors
Date:8/20/2013

Cleveland (PRWEB) August 20, 2013

ChanTest, a Contract Research Organization and world leader in ion channel drug safety and discovery, announces initiation of a project funded by the US Food and Drug Administration’s (FDA) Center for Tobacco Products (CTP). CTP’s mission is to improve our understanding of the pharmacology of tobacco product substituent compounds and to enhance the regulation of tobacco products.

The FDA’s authority to regulate the manufacture, distribution, and marketing of tobacco products to protect public health stems from The Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act), which became law on June 22, 2009. The FDA's funding of this ChanTest project falls under a regulatory science initiative calling for innovation in technology to convert basic science to real-world applications.

The goals of the one-year study are to develop cell lines that express human nicotinic receptor subtypes, and to optimize high-throughput testing of exploratory compounds against nicotinic receptors in automated patch clamp and fluorometric plate-based assays. The results of the study will help the FDA gain a better understanding of the pharmacology of human nicotinic receptor subtypes and provide screening platforms for efficient characterization of tobacco-related substances.

“This project will expand our repertoire of ligand-gated ion channel test systems in the therapeutically important neuronal nicotinic receptor family. We look forward to benefiting from FDA’s extensive background in this class of targets” said ChanTest Director of Pharmacology, Glenn Kirsch, Ph.D.

Dr. Arthur “Buzz” Brown, M.D., Ph.D., ChanTest Founder and CEO, added “ChanTest has unique expertise in ion channel cell line development and cell-based functional assays, as demonstrated by our track record in ion channel safety and discovery services serving the pharmaceutical industry. We view th
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. ChanTest Announces a Complimentary Webinar on the Use of the xCELLigence System
2. ChanTest Announces Their Second User Meeting: Partnerships in Drug Discovery
3. ChanTest Introduces the CardioChannelGram™ and SaVety Assessment
4. ChanTest Develops New Cardiotoxicity and Contractility Assay with Human Stem Cell Cardiomyocytes
5. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
6. Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
7. Research Alert -- Empire Asset Management Co. Initiates Coverage on Exact Sciences (NASDAQ: EXAS)
8. Applied Genetics Initiates Commercial Operation
9. Snoasis Medical Initiates Distribution in Japan Through Hausten Healthcare
10. Medbox, Inc. Initiates "Responsible Consumption" Campaign for Marijuana in Recreational States
11. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... May 29, 2015 Delcath Systems, Inc. ... medical device company focused on oncology with an ... liver cancers, announces that results of a large, ... melanoma patients with hepatic metastases with the Delcath ... in an on-line abstract at the American Society ...
(Date:5/29/2015)... May 29, 2015  Caris Life Sciences ® ... the promise of precision medicine, today announced the ... the clinical utility of Caris Molecular Intelligence ® ... in helping to identify targeted treatment options for ... of the studies, results of which are to ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 Results from ... talimogene laherparepvec and its ability to reduce the size ... have been published in the Journal of Clinical Oncology. ... with stages IIIB, IIIC and IV melanoma, a potentially ... the study was to evaluate the safety and efficacy ...
(Date:5/28/2015)... 28, 2015 Research ... addition of Jain PharmaBiotech,s new report  "Alzheimer ...  to their offering.       (Logo: ... challenge in management. With nearly 8 million ... major markets of the world and anticipated ...
Breaking Biology Technology:Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 2Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 3Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 4Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 5Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 2Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 3Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 4Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 5Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 6Study Published in Journal of Clinical Oncology Reports Talimogene Laherparepvec Improvesdurable Responses in Patients with Advanced Melanoma 2Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 2Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 3
... 2011 Engineers and scientists collaborating at Harvard University ... world,s first programmable nanoprocessor. The groundbreaking prototype computer ... journal Nature , represents a significant step forward ... assembled from synthesized nanometer-scale components. It also represents ...
... 9, 2011 Talecris Biotherapeutics Holdings Corp. (Nasdaq: TLCR) ... special meeting of shareholders, to be held on February ... Research Triangle Park Marriott, 4700 Guardian Drive, Durham, North Carolina 27703. ... announced merger agreement under which Grifols (GRF.MC) will acquire ...
... LOUIS, Feb. 9, 2011 HIGHLIGHTS:2010 Results (all ... Q4 2010 reported sales were $582 million, a new quarterly high. ... currency adjusted basis, respectively.  Full year 2010 sales increased 6% and ... Q4 2010 reported diluted EPS was $0.76. Excluding restructuring ...
Cached Biology Technology:Researchers at Harvard and MITRE produce world's first programmable nanoprocessor 2Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 2Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 3Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 4Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 5Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 6Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 7Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 8Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 9Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 10Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 11Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 12Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 13
(Date:5/18/2015)... 2015 Fingerprint Cards (FPC) has received ... FPC1155 and FPC1035 from one if its module partners. Deliveries ... Q3 2015 and the sensors will be used by smartphone ... for 2015 hereby amount to 740 MSEK to date. In ... MSEK and a number of smaller orders not separately communicated ...
(Date:5/14/2015)... 14, 2015  Verificient Technologies, Inc., a ... online remote proctoring, announced a new alliance ... and creator of the Canvas Learning Management ... companies will benefit from the seamless integration ... As a fully integrated multifactor biometrics behavioral ...
(Date:5/11/2015)...  Through a well-rounded UAS delegation representing private industry, government, ... showing at AUVSI,s Unmanned 2015 conference last week in ... UAS industry met with over 200 hundred people ... the UAS ecosystem. "Our message is clear ... Aerospace Rich Knoll . "If you want to fly ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2
... $7 million grant from the National Institutes of ... Hospital translate new scientific findings and technological developments ... grant designates Nationwide Children,s Hospital as a Paul ... of three national award recipients in 2010. ...
... comparing two species of ants, Shelley Berger, PhD, the ... Pennsylvania, and colleagues Danny Reinberg, PhD, New York University, ... an important new avenue of research for epigenetics -- ... particular genes affects an organism,s characteristics, development, and even ...
... message: Find out what,s new (and important) ... international reporters, Book hotel rooms now for the best selection, ... 1. Find out what,s new (and important) in the ... Fall Meeting returns to the Moscone Convention Center, located at ...
Cached Biology News:$7 million grant designates Nationwide Children's as Wellstone Center 2Genome comparison of ants establishes new model species for molecular research 2Genome comparison of ants establishes new model species for molecular research 3Genome comparison of ants establishes new model species for molecular research 4AGU 2010 Fall Meeting: News media registration opens, book hotels now 2AGU 2010 Fall Meeting: News media registration opens, book hotels now 3AGU 2010 Fall Meeting: News media registration opens, book hotels now 4
... Mammalian Protein Extraction Reagent is ... solution that means no scraping, ... sonication! With M-PER Reagent, rapid ... minutes at room temperature, yielding ...
Application: for RNase- decontamination , Registered Trademark of Ambion. ,Special grade: for molecular biology Density: 1.00 g/mL (20 C) Suitab tst: RNase decontamination in accordance...
... Designed to meet the needs ... animal component-free medium supports fast ... cell densities, while maintaining high ... protein production using the Baculovirus ...
A set of five proteins which can be used to calibrate a Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) or Electrospray Ionization (ESI) mass spectrometer....
Biology Products: